top of page

CLINICAL TRIALS

Focused on Cures

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients

INNOVATIVE

Technology

Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

We are the first company to remove HIV genomes from animals and generate functional cures for HIV.

NOVEL

Approach

SAFE

Targets non-human viral genomes minimizing chance of off-target cuts

CURATIVE

Removes non-human DNA to return the genome to normal or near-normal

EFFICIENT

Excision products require one-time gene edit to remove the viral genome permanently

“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

News

LATEST

GLOBE NEWSWIRE

August 2021

Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure

GLOBE NEWSWIRE

September 2022

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

GLOBE NEWSWIRE

September 2022

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

GLOBE NEWSWIRE

September 2022

OUR

Partners

Untitled design_edited.jpg

Olive Tree Capital.png

Abstract Ventures

info@excisionbio.com

IR@excisionbio.com

499 Jackson Street
San Francisco, CA 94111
USA

© 2022 Excision BioTherapeutics. All Rights Reserved.

bottom of page